---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-244725"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T12:56:23.340180+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tempest Therapeutics Q2 net loss $7.1M; cash $68.5M; appoints Ronit Simantov to board

## Summary
- Closed merger and $30M PIPE in June 2021; cash position $68.5M vs $18.8M at Dec 2020; runway extends into Q1’23.
- Net loss $7.1M ($7.63 per share) vs $5.2M ($11.42) in Q2 2020; six-month net loss $12.4M ($17.30).
- TPST-1120 selected 600mg BID RP2D; observed deep confirmed partial response in combination with nivolumab in RCC.
- Appointed Ronit Simantov, M.D. as Class III director effective Aug 6, 2021; granted option for 6,635 shares.
- TREX-1 inhibitor advanced to picomolar IC50 potency; in vivo efficacy shown in mouse tumor model.

## SEC filing metadata
- accession: 0001193125-21-244725
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312521244725/0001193125-21-244725-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312521244725/d186207d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-244725
- JSON: https://secwatch.observer/filing/0001193125-21-244725.json
- Plain text: https://secwatch.observer/filing/0001193125-21-244725.txt

## Key facts
- Executive change
  Ronit Simantov was appointed as Class III director at Tempest Therapeutics, Inc..
  - Action: appointed
  - Role: Class III director
  source text: Effective as of August 6, 2021, the Company’s Board of Directors (the “Board”) appointed Ronit Simantov, M.D. to serve as Class III director of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312521244725/0001193125-21-244725-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.